Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crovalimab Phase III study in Guillain-Barré syndrome
jRCT2061220061Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Oct 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in Guillain-Barré syndrome (GBS) comparing Crovalimab + IVIg with Placebo + IVIg (2 arms). Primary endpoint: Percentage of participants who reach FG <= 1 on the GBS-DS at Week 24. Started Oct 2022; status: completed.
02
Drugs
crovalimab
03
Conditions
Guillain-Barré syndrome (GBS)
Beyond the preview
Go deeper on jRCT2061220061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061220061.